Search results for "breast neoplasms"

showing 10 items of 804 documents

Mid-region parathyroid hormone-related protein (PTHrP) and gene expression of MDA-MB231 breast cancer cells.

2007

Abstract We have previously shown that PTHrP(38–94) amide restrains growth and invasion in vitro, causes striking toxicity and accelerates death of some breast cancer cell lines, the most responsive being MDA-MB231, for which tumorigenesis was also attenuated in vivo. We have also demonstrated that mid-region PTHrP gains access to the nuclear compartment of these cells and displays DNA-binding properties in vitro by recognizing targets in both cellular chromatin and isolated oligonucleotides. Here, we examined whether PTHrP(38–94) amide was able to modulate gene expression of MDA-MB231 cells, employing a combination of conventional, differential display and semi-quantitative multiplex PCR t…

Differential displayParathyroid hormone-related proteinChemistryClinical BiochemistryMolecular Sequence DataParathyroid Hormone-Related ProteinBreast Neoplasmsmedicine.disease_causeBiochemistryIn vitroChromatinGene Expression Regulation NeoplasticCell Line TumorGene expressionmedicineCancer researchCytotoxic T cellHumansCarcinogenesisMolecular BiologyReprogrammingBiomarkersChromosomes Human Pair 8Biological chemistry
researchProduct

Polyoxygenated Cyclohexenes and Other Constituents of Cleistochlamys kirkii Leaves.

2016

Thirteen new metabolites, including the polyoxygenated cyclohexene derivatives cleistodiendiol (1), cleistodienol B (3), cleistenechlorohydrins A (4) and B (5), cleistenediols A-F (6-11), cleistenonal (12), and the butenolide cleistanolate (13), 2,5-dihydroxybenzyl benzoate (cleistophenolide, 14), and eight known compounds (2, 15-21) were isolated from a MeOH extract of the leaves of Cleistochlamys kirkii. The purified metabolites were identified by NMR spectroscopic and mass spectrometric analyses, whereas the absolute configurations of compounds 1, 17, and 19 were established by single-crystal X-ray diffraction. The configuration of the exocyclic double bond of compound 2 was revised base…

Double bondStereochemistryCyclohexenesPlasmodium falciparumCyclohexenePharmaceutical ScienceBreast Neoplasms01 natural sciencesAnalytical Chemistrychemistry.chemical_compoundAntimalarialsInhibitory Concentration 50X-Ray DiffractionDrug DiscoveryCyclohexenesHumansta116metabolitesCleistochlamys kirkiiButenolidePharmacologychemistry.chemical_classificationMolecular Structure010405 organic chemistryOrganic Chemistryspectrometric analysesMass spectrometricAntineoplastic Agents Phytogenic3. Good health0104 chemical sciencesPlant Leaves010404 medicinal & biomolecular chemistryCleistophenolideHEK293 CellsComplementary and alternative medicinechemistryMolecular MedicineJournal of natural products
researchProduct

Dryofragin, a phloroglucinol derivative, induces apoptosis in human breast cancer MCF-7 cells through ROS-mediated mitochondrial pathway

2012

Dryofragin is a phloroglucinol derivative extracted from Dryopteris fragrans (L.) Schott. In this study, the anticancer activity of dryofragin on human breast cancer MCF-7 cells was investigated. Dryofragin inhibited the growth of MCF-7 cells in a time and concentration-dependent manner. The cell viability was measured using MTT assay. After treatment with dryofragin for 72, 48 and 24 h, the IC₅₀ values were 27.26, 37.51 and 76.10 μM, respectively. Further analyses of DNA fragmentation and Annexin V-PI double-labeling indicated an induction of apoptosis. Dryofragin-treatment MCF-7 cells had a significantly accumulation of reactive oxygen species (ROS), as well as an increased percentage of …

DryopterisApoptosisBreast NeoplasmsPhloroglucinolBiologyToxicologyAnnexinCell Line TumorHumansMTT assayBreastViability assayMembrane Potential Mitochondrialchemistry.chemical_classificationReactive oxygen speciesGeneral MedicineAntineoplastic Agents PhytogenicMolecular biologyMitochondriaCell biologychemistryMCF-7Cell cultureApoptosisDNA fragmentationFemaleReactive Oxygen SpeciesSignal TransductionChemico-Biological Interactions
researchProduct

PED Mediates AKT-Dependent Chemoresistance in Human Breast Cancer Cells

2005

Abstract Killing of tumor cells by cytotoxic therapies, such as chemotherapy or gamma-irradiation, is predominantly mediated by the activation of apoptotic pathways. Refractoriness to anticancer therapy is often due to a failure in the apoptotic pathway. The mechanisms that control the balance between survival and cell death in cancer cells are still largely unknown. Tumor cells have been shown to evade death signals through an increase in the expression of antiapoptotic molecules or loss of proapoptotic factors. We aimed to study the involvement of PED, a molecule with a broad antiapoptotic action, in human breast cancer cell resistance to chemotherapeutic drugs–induced cell death. We show…

EXPRESSIONAdultCancer ResearchProgrammed cell deathmedicine.medical_treatmentINHIBITIONApoptosisBreast NeoplasmsProtein Serine-Threonine KinasesDNA AntisenseACTIVATIONBreast cancerTransduction GeneticCell Line TumorProto-Oncogene ProteinsComplementary DNAmedicineHumansCytotoxic T cellPROTEIN-KINASE-CProtein kinase BAgedNeoplasm StagingChemotherapybusiness.industryDEATHIntracellular Signaling Peptides and ProteinsJNK Mitogen-Activated Protein KinasesIN-VITROCHEMOTHERAPYMiddle AgedPhosphoproteinsmedicine.diseasePED/PEA-15Up-RegulationEnzyme ActivationOncologyDrug Resistance NeoplasmApoptosisCancer cellImmunologyCancer researchFemalePTEN GENEApoptosis Regulatory ProteinsbusinessProto-Oncogene Proteins c-aktCancer Research
researchProduct

Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.

2011

The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC). In a group of 51 elderly women (aged 76.4 ± 5.0 years) considered for adjuvant aromatase inhibitors for EBC, 24 patients with T-scores ≥ -2 and no prevalent fractures received anastrozole 1 mg/day (group A), and 27 patients with T-scores < -2, or with T-scores ≥ -2 and prevalent fractures (group B), received anastrozole (1 mg/day) plus risedronate (35 mg/week). Both groups received supplementation with 1 g calcium carbonate and 800 IU vitamin D per day. Differen…

Endocrinology Diabetes and MetabolismOsteoporosisSeverity of Illness IndexCohort StudiesEndocrinologyBone DensityOrthopedics and Sports MedicineVitamin DAromataseOsteoporosis PostmenopausalAged 80 and overBone Density Conservation AgentsbiologyAromatase InhibitorsEtidronic AcidGeneral MedicineCombined Modality Therapymedicine.anatomical_structureFemaleRisedronic Acidmedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyAntineoplastic Agents HormonalUrologyAnastrozoleBreast NeoplasmsAnastrozoleCalcium CarbonateNitrilesmedicineVitamin D and neurologyHumansBone ResorptionAgedNeoplasm StagingFemoral neckTrochanterbusiness.industryBone fractureTriazolesmedicine.diseaseSurgeryEarly breast cancer Anastrozole Osteoporosis Vertebral fractures ElderlyDietary SupplementsOrthopedic surgerybiology.proteinbusinessOsteoporotic FracturesFollow-Up Studies
researchProduct

Role of the protein C receptor in cancer progression

2014

The hemostatic system plays pleiotropic roles in cancer progression by shaping the tumor microenvironment and metastatic niches through thrombin-dependent fibrin deposition and platelet activation. Expanding experimental evidence implicates coagulation protease receptors expressed by tumor cells as additional players that directly influence tumor biology. Pro-angiogenic G protein-coupled signaling of TF through protease activated receptor 2 and regulation of tumor cell and vascular integrins through ligation by alternative spliced TF are established pathways driving tumor progression. Our recent work shows that the endothelial protein C receptor (EPCR), a stem cell marker in hematopoietic, …

Endothelial protein C receptorTumor microenvironmentCD30Endothelial Protein C ReceptorBreast NeoplasmsReceptors Cell SurfaceHematologyBiologyStem cell markerArticleAntigens CDTumor progressionCancer stem cellDisease ProgressionTumor MicroenvironmentCancer researchAnimalsHumansFemalePlatelet activationBlood CoagulationProtease-activated receptor 2Signal TransductionThrombosis Research
researchProduct

A Genome-wide Association Study of Early-onset Breast Cancer Identifies PFKM as a Novel Breast Cancer Gene and Supports a Common Genetic Spectrum for…

2014

Abstract Early-onset breast cancer (EOBC) causes substantial loss of life and productivity, creating a major burden among women worldwide. We analyzed 1,265,548 Hapmap3 single-nucleotide polymorphisms (SNP) among a discovery set of 3,523 EOBC incident cases and 2,702 population control women ages ≤ 51 years. The SNPs with smallest P values were examined in a replication set of 3,470 EOBC cases and 5,475 control women. We also tested EOBC association with 19,684 genes by annotating each gene with putative functional SNPs, and then combining their P values to obtain a gene-based P value. We examined the gene with smallest P value for replication in 1,145 breast cancer cases and 1,142 control …

EpidemiologyPopulationGenome-wide association studySingle-nucleotide polymorphismBreast NeoplasmsBiologyPolymorphism Single NucleotideArticle03 medical and health sciences0302 clinical medicineBreast cancerSDG 3 - Good Health and Well-beingPhosphofructokinase-1 Muscle TypeGenetic predispositionmedicineBiomarkers TumorSNPHumansGenetic Predisposition to DiseaseeducationGene030304 developmental biologyGenetics0303 health scienceseducation.field_of_studyMiddle Agedmedicine.disease3. Good healthOncologyPFKM030220 oncology & carcinogenesisCase-Control StudiesFemaleGenome-Wide Association Study
researchProduct

The Binomial “Inflammation-Epigenetics” in Breast Cancer Progression and Bone Metastasis: IL-1β Actions Are Influenced by TET Inhibitor in MCF-7 Cell…

2022

The existence of a tight relationship between inflammation and epigenetics that in primary breast tumor cells can lead to tumor progression and the formation of bone metastases was investigated. It was highlighted how the induction of tumor progression and bone metastasis by Interleukin-1 beta, in a non-metastatic breast cancer cell line, MCF-7, was dependent on the de-methylating actions of ten-eleven translocation proteins (TETs). In fact, the inhibition of their activity by the Bobcat339 molecule, an inhibitor of TET enzymes, determined on the one hand, the modulation of the epithelial-mesenchymal transition process, and on the other hand, the reduction in the expression of markers of bo…

Epithelial-Mesenchymal TransitionDNA methylation; bone metastasis; inflammation; Interleukin-1β; ten-eleven translocation proteins; MCF-7 cell lineInterleukin-1betaBreast NeoplasmsBone NeoplasmsMCF-7 cell lineCatalysisEpigenesis GeneticInorganic ChemistrySettore BIO/13 - Biologia ApplicataCell Line TumorHumansPhysical and Theoretical ChemistryMolecular BiologySpectroscopybone metastasisDNA methylationten-eleven translocation proteinsOrganic ChemistryGeneral MedicineInterleukin-1βComputer Science ApplicationsSettore BIO/18 - GeneticainflammationMCF-7 CellsFemaleInflammatory Breast NeoplasmsInternational Journal of Molecular Sciences
researchProduct

Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Ef…

2021

Objective Eribulin mesylate (EM) is a fully synthetic macrocyclic ketone analogue of the marine natural product halichondrin. EM has been reported to be active in metastatic breast cancer. In this paper, we report efficacy and safety of data of EM in a retrospective, real-world series of patients with poor prognosis, hormone-refractory, or triple-negative metastatic breast cancer. Materials and methods The analysis was carried out at 4 interrelated oncology centers. EM was delivered at the dose of 1.4 mg/m2 in 100 mL of normal saline over 2 to 5 minutes on days 1 and 8 every 21 days. EM was continued until disease progression or unacceptable toxicity. Side effects were reported every cycle …

Eribulin MesylateOncologyAdultCancer Researchmedicine.medical_specialtyNeoplasms Hormone-Dependenteribulin mesylateSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntineoplastic AgentsTriple Negative Breast Neoplasmstriple negative03 medical and health sciences0302 clinical medicineStable DiseaseBreast cancerbreast cancerInternal medicineAntineoplastic Combined Chemotherapy Protocolshormonal refractorymedicineHumans030212 general & internal medicineFuransSalineTriple-negative breast cancerAgedRetrospective StudiesChemotherapybusiness.industryKetonesMiddle Agedmedicine.diseaseMetastatic breast cancerSettore MED/18 - Chirurgia GeneraleTreatment OutcomeOncology030220 oncology & carcinogenesisToxicityFemalebusiness
researchProduct

Situación de la investigación en el cribado de cáncer de mama en España: implicaciones para la prevención

2012

ResumenObjetivoLa finalización del despliegue de los programas de detección precoz de cáncer de mama en todas las comunidades autónomas de España ha facilitado el inicio de una investigación conjunta, con información procedente de varios programas, orientada a mejorar su efectividad.MétodosSe ha construido una cohorte de más de 1 millón de mujeres cribadas para evaluar el riesgo y los determinantes de los resultados falsos positivos. Se ha evaluado el impacto del cambio de técnica de mamografía analógica a digital y se está estudiando el cáncer de intervalo y los resultados falsos negativos.ResultadosLos resultados ofrecen información muy útil, desde el punto de vista de salud pública, para…

Evaluation studies (topic)Neoplasia de mamaResearch designDetección precoz del cáncerDiseño de la investigaciónPublic Health Environmental and Occupational HealthEstudios de evaluación (como tema)Breast neoplasmsEarly cancer detection
researchProduct